A Phase 4 interventional study of HES 130/0.42 + electrolyte solution and Albumin + electrolyte solution in Renal Insufficiency, sponsored by B. Braun Melsungen AG. Terminated at 2 sites in Germany. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-09-28.
Sponsored by B. Braun Melsungen AG · Phase 4, Interventional, and Treatment
This investigational study will investigate two different volume replacement regimes in patients suffering from compromised renal function.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's enrollment of 2 is below the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →B. Braun Melsungen AG is the lead sponsor of 46 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion:
HES 130/0.42 + Sterofundin ISO
Drug: HES 130/0.42 + electrolyte solution
Albumin + NaCl 0.9%
Drug: Albumin + electrolyte solution
Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
Impact of two different volume replacement regimes on base excess in patients with reduced renal function
Time frame: from pre-operative assessment until last evaluation of data i.e. 5th (hospital) and 60th postoperative day (follow-up)
Renal function, hemodynamics, blood loss, amount of given blood products, electrolytes, outcome and other data like concomitant medication
Time frame: inta-/postoperative
This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
B. Braun Melsungen AG